GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Forest Laboratories Inc (FRA:FQX) » Definitions » Cyclically Adjusted Revenue per Share

Forest Laboratories (FRA:FQX) Cyclically Adjusted Revenue per Share : €0.00 (As of Mar. 2014)


View and export this data going back to . Start your Free Trial

What is Forest Laboratories Cyclically Adjusted Revenue per Share?

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Revenue per Share and the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years.

Forest Laboratories's adjusted revenue per share for the three months ended in Mar. 2014 was €2.828. Add all the adjusted revenue per share for the past 10 years together and divide the count will get our Cyclically Adjusted Revenue per Share, which is €0.00 for the trailing ten years ended in Mar. 2014.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the Cyclically Adjusted Revenue Growth Rate using Cyclically Adjusted Revenue per Share data.

As of today (2024-05-29), Forest Laboratories's current stock price is €72.50. Forest Laboratories's Cyclically Adjusted Revenue per Share for the quarter that ended in Mar. 2014 was €0.00. Forest Laboratories's Cyclically Adjusted PS Ratio of today is .


Forest Laboratories Cyclically Adjusted Revenue per Share Historical Data

The historical data trend for Forest Laboratories's Cyclically Adjusted Revenue per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Forest Laboratories Cyclically Adjusted Revenue per Share Chart

Forest Laboratories Annual Data
Trend Mar05 Mar06 Mar07 Mar08 Mar09 Mar10 Mar11 Mar12 Mar13 Mar14
Cyclically Adjusted Revenue per Share
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - - -

Forest Laboratories Quarterly Data
Jun09 Sep09 Dec09 Mar10 Jun10 Sep10 Dec10 Mar11 Jun11 Sep11 Dec11 Mar12 Jun12 Sep12 Dec12 Mar13 Jun13 Sep13 Dec13 Mar14
Cyclically Adjusted Revenue per Share Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Competitive Comparison of Forest Laboratories's Cyclically Adjusted Revenue per Share

For the Drug Manufacturers - Specialty & Generic subindustry, Forest Laboratories's Cyclically Adjusted PS Ratio, along with its competitors' market caps and Cyclically Adjusted PS Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Forest Laboratories's Cyclically Adjusted PS Ratio Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Forest Laboratories's Cyclically Adjusted PS Ratio distribution charts can be found below:

* The bar in red indicates where Forest Laboratories's Cyclically Adjusted PS Ratio falls into.



Forest Laboratories Cyclically Adjusted Revenue per Share Calculation

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Revenue per Share and the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years.

What is Cyclically Adjusted Revenue per Share? How do we calculate Cyclically Adjusted Revenue per Share?

Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years. Let's use an example to explain.

If we want to calculate the Cyclically Adjusted Revenue per Share of Wal-Mart (WMT) for Dec. 31, 2010, we need to have the inflation data and the revenue per share from 2001 through 2010.

We adjusted the 2001 revenue per share data with the total inflation from 2001 through 2010 to the equivalent revenue in 2010. If the total inflation from 2001 to 2010 is 40%, and Wal-Mart's revenue is $1 a share in 2001, then the 2001's equivalent revenue in 2010 is $1.4 a share. If Wal-Mart's revenue is $1 again in 2002, and the total inflation from 2002 through 2010 is 35%, then the equivalent 2002 revenue in 2010 is $1.35. So on and so forth, you get the equivalent revenue per share of past 10 years. Then you add them together and divided the sum by the count to get Cyclically Adjusted Revenue per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

For example, Forest Laboratories's adjusted Revenue per Share data for the three months ended in Mar. 2014 was:

Adj_RevenuePerShare= Revenue per Share /CPI of Mar. 2014 (Change)*Current CPI (Mar. 2014)
=2.828/99.6945*99.6945
=2.828

Current CPI (Mar. 2014) = 99.6945.

Forest Laboratories Quarterly Data

Revenue per Share CPI Adj_RevenuePerShare
200406 1.713 80.037 2.134
200409 1.921 80.121 2.390
200412 1.671 80.290 2.075
200503 1.385 81.555 1.693
200506 1.657 82.062 2.013
200509 1.740 83.876 2.068
200512 1.875 83.032 2.251
200603 1.923 84.298 2.274
200606 1.979 85.606 2.305
200609 2.016 85.606 2.348
200612 2.110 85.142 2.471
200703 2.076 86.640 2.389
200706 2.148 87.906 2.436
200709 2.085 87.964 2.363
200712 2.130 88.616 2.396
200803 2.218 90.090 2.454
200806 2.016 92.320 2.177
200809 2.261 92.307 2.442
200812 2.439 88.697 2.741
200903 2.437 89.744 2.707
200906 2.373 91.003 2.600
200909 2.405 91.120 2.631
200912 2.404 91.111 2.630
201003 2.557 91.821 2.776
201006 2.899 91.962 3.143
201009 2.888 92.162 3.124
201012 2.957 92.474 3.188
201103 2.816 94.283 2.978
201106 2.792 95.235 2.923
201109 3.105 95.727 3.234
201112 3.434 95.213 3.596
201203 2.977 96.783 3.067
201206 2.433 96.819 2.505
201209 2.209 97.633 2.256
201212 2.052 96.871 2.112
201303 2.359 98.209 2.395
201306 2.352 98.518 2.380
201309 2.362 98.790 2.384
201312 2.350 98.326 2.383
201403 2.828 99.695 2.828

Add all the adjusted revenue per share together and divide 10 will get our Cyclically Adjusted Revenue per Share.


Forest Laboratories  (FRA:FQX) Cyclically Adjusted Revenue per Share Explanation

If a company grows much fast than inflation, Cyclically Adjusted Revenue per Share may underestimate the company's revenue. Cyclically Adjusted PS Ratio can seem to be too high even the actual PS Ratio is low.

For the Cyclically Adjusted PS Ratio, the revenue per share of the past 10 years are inflation-adjusted and averaged. The result is used for P/S calculation. Since it looks at the average over the last 10 years, the Cyclically Adjusted PS Ratio is also called CAPS Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted revenue per share of a company over the past 10 years.


Be Aware

Cyclically Adjusted PS Ratio works better for cyclical companies. It gives you a better idea on the company's real revenue value.


Forest Laboratories Cyclically Adjusted Revenue per Share Related Terms

Thank you for viewing the detailed overview of Forest Laboratories's Cyclically Adjusted Revenue per Share provided by GuruFocus.com. Please click on the following links to see related term pages.


Forest Laboratories (FRA:FQX) Business Description

Industry
Traded in Other Exchanges
N/A
Address
Forest Laboratories, Inc. is a Delaware corporation organized in 1956. The Company develops, manufactures and sells branded forms of ethical drug products most of which require a physician's prescription. The Company's most important United States products are marketed directly, or 'detailed,' to physicians by its salesforces. It emphasizes detailing to physicians of those branded ethical drugs which have the most potential for growth and benefit to patients. The Company also develops and introduces new products, including products developed in collaboration with licensing partners. The Company's products include those developed by it and those acquired from other pharmaceutical companies and integrated into its marketing and distribution systems. It actively promotes in the United States those branded products which have the most potential for growth and patient benefit, and which enable its salesforces to concentrate on groups of physicians who are high prescribers of its products. Such products include: Lexapro, its SSRI for the treatment of major depression in adults and adolescents and GAD in adults; Namenda, its NMDA antagonist for the treatment of moderate and severe Alzheimer's disease; Bystolic, its beta-blocker for the treatment of hypertension; and Savella, its newest product, an SNRI for the management of fibromyalgia. The Company's United Kingdom and Ireland subsidiaries sell both ethical products and over-the-counter preparations. Their most important products include Sudocrem, a topical preparation for the treatment of diaper rash; Colomycin, an antibiotic used in the treatment of cystic fibrosis; Infacol, used to treat infant colic; and Exorex, used in the treatment of eczema and psoriasis. The pharmaceutical industry is subject to comprehensive government regulation which substantially increases the difficulty and cost incurred in obtaining the approval to market newly proposed drug products and maintaining the approval to market existing drugs.

Forest Laboratories (FRA:FQX) Headlines

No Headlines